This week’s newsletter covers Trump’s executive order directing cannabis rescheduling to Schedule III, federal enforcement challenges around intoxicating hemp products, new research on cannabinoids and ovarian cancer, sleep quality, obesity, cardiovascular health, and a rare case of post-cessation psychosis.
Noteworthy Read
Trump Signs Executive Order Directing Federal Government to Move Cannabis to Schedule III (Ganjapreneur)
President Donald Trump signed an executive order yesterday directing the U.S. Attorney General to begin reclassifying cannabis under federal law from a Schedule I substance to a Schedule III controlled substance, a shift that acknowledges medical value and could ease research barriers and regulatory burdens on the cannabis industry. President Biden’s administration had previously recommended this change during his term.
During the press conference, an advisor also stated that under the new guidance, Medicare recipients could begin receiving “full-spectrum CBD” free of charge under their plans as soon as April 2026, with a doctor’s recommendation.
Read the articleView more in CBD
More Noteworthy Reading
FDA and DEA May Lack Resources to Enforce Federal Hemp Product Ban (Cannabis Business Times)
Regulators and industry observers warn that limited staffing, unclear guidance, and overlapping jurisdiction could undermine enforcement of the new federal ban on intoxicating hemp-derived products.
Read moreView more in Synthetic Cannabinoids
Blue Dream’s Revenge: Why the Cannabis Market Needs Heirloom Genetics (MJBizDaily)
As modern breeding prioritizes high-THC novelty strains, industry veterans argue that stable, heirloom genetics like Blue Dream offer consistency, resilience, and consumer trust that today’s market is missing.
Read moreView more in THC
Chinese Study: CBD and THC May Provide New Ovarian Cancer Treatments (Healthline)
Researchers in China found that both CBD and THC reduced tumor growth and triggered cancer cell death in ovarian cancer models, suggesting cannabinoids could be used to complement or develop new therapies.
Read moreView more in CBD
Research Round-Up
Effectiveness of Cannabinoids on Sleep Quality (Sleep Medicine Reviews)
This systematic review found moderate evidence that cannabinoids—particularly THC and mixed cannabinoid formulations—can improve sleep outcomes, while CBD’s effects remain inconsistent and highly dose-dependent.
Read moreView more in THC
Cannabis Use Associated With Lower Rates of Obesity and Metabolic Syndrome (NORML)
An analysis of population-level data found that adults who use cannabis have lower rates of obesity, insulin resistance, and metabolic syndrome, even after controlling for age, diet, and lifestyle factors.
Read moreView more in Endocannabinoid System
Dietary Hempseed and Cardiovascular Health (Frontiers in Nutrition)
A review of clinical and preclinical studies suggests that hempseed consumption may support heart health by improving lipid profiles, reducing inflammation, and supporting vascular function due to its fatty acid and antioxidant content.
Read moreView more in CBD
New-Onset Psychosis Following Cannabis Discontinuation (Psychiatry Research Case Reports)
A rare case report documents acute psychosis following abrupt cannabis cessation, raising questions about withdrawal-related neurochemical changes and highlighting the need for clinical awareness in heavy users.
Read moreView more in Endocannabinoid System
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to shine a light on the latest plant medicine research and bring these important stories to our readers every week.
Be the first to comment